Suppr超能文献

沙特阿拉伯非酒精性脂肪性肝病患者心血管疾病和慢性肾脏病的危险因素。

The risk factors for cardiovascular disease and chronic kidney disease in patients with nonalcoholic fatty liver disease in Saudi Arabia.

作者信息

Mohammedsaeed Walaa, Al Malki Abdullah, Alsayed Salma

机构信息

From the Department of Clinical Laboratory Sciences (Mohammedsaeed), Faculty of Applied Medical Science, Taibah University, and from the Department of Pathology and Laboratory Medicine (Al Malki, Alsayed), Prince Mohammed Bin Abdul-Aziz Hospital, Al-Madinah Al-Munawarah, Kingdom of Saudi Arabia.

出版信息

Saudi Med J. 2025 May;46(5):478-490. doi: 10.15537/smj.2025.46.5.20240901.

Abstract

OBJECTIVES

To identify potential risk factors for chronic kidney disease (CKD) and cardiovascular disease (CVD) in Saudi Arabian patients with non-alcoholic fatty liver disease (NAFLD).

METHODS

A 6-year prospective cohort study was carried out from January 2018 to January 2023, enrolling 1,500 patients. Data were initially collected between January 2018-2019, and follow-up assessments were carried out annually from 2020-2023. Patients were evaluated using biomarker analyses, and medical records were reviewed to assess the incidence of CVD and CKD. Biomarker levels, including blood creatinine, urine albumin, glomerular filtration rate (GFR), atherogenic index of plasma (AIP), and other key parameters, were monitored throughout the study.

RESULTS

Of the 1500 patients, 735 (49%) were diagnosed with NAFLD in 2018, while 765 (51%) did not have the condition. Compared to non-NAFLD patients, those with NAFLD exhibited elevated blood creatinine levels, lower GFR, and higher urine albumin, a key marker of kidney damage that is strongly linked to accelerated CKD progression and increased cardiovascular risk. Furthermore, NAFLD patients had a significantly higher AIP. Over the 4-year follow-up, these individuals showed a notable rise in the incidence of CKD and CVD.

CONCLUSION

Non-alcoholic fatty liver disease is associated with alterations in lipid profiles, elevated high-sensitivity C-reactive protein (hs-CRP), and elevated aspartate aminotransferase (AST), all of which may contribute to early CKD and CVD development. Older, obese individuals with NAFLD, high triglyceride, AST, and hs-CRP levels are at an elevated risk for these diseases.

摘要

目的

确定沙特阿拉伯非酒精性脂肪性肝病(NAFLD)患者慢性肾脏病(CKD)和心血管疾病(CVD)的潜在危险因素。

方法

从2018年1月至2023年1月进行了一项为期6年的前瞻性队列研究,纳入1500名患者。数据最初于2018 - 2019年1月收集,并于2020 - 2023年每年进行随访评估。使用生物标志物分析对患者进行评估,并审查病历以评估CVD和CKD的发病率。在整个研究过程中监测生物标志物水平,包括血肌酐、尿白蛋白、肾小球滤过率(GFR)、血浆致动脉粥样硬化指数(AIP)和其他关键参数。

结果

在1500名患者中,735名(49%)在2018年被诊断为NAFLD,而765名(51%)没有该疾病。与非NAFLD患者相比,NAFLD患者的血肌酐水平升高、GFR降低且尿白蛋白升高,尿白蛋白是肾损伤的关键标志物,与CKD进展加速和心血管风险增加密切相关。此外,NAFLD患者的AIP显著更高。在4年的随访中,这些个体的CKD和CVD发病率显著上升。

结论

非酒精性脂肪性肝病与血脂谱改变、高敏C反应蛋白(hs-CRP)升高和天冬氨酸转氨酶(AST)升高有关,所有这些都可能导致早期CKD和CVD的发生。年龄较大、肥胖的NAFLD患者,若甘油三酯、AST和hs-CRP水平较高,则患这些疾病的风险更高。

相似文献

4
Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease.
Nephrol Dial Transplant. 2019 Mar 1;34(3):449-457. doi: 10.1093/ndt/gfx381.
5
New Nonalcoholic Fatty Liver Disease and Fibrosis Progression Associate With the Risk of Incident Chronic Kidney Disease.
J Clin Endocrinol Metab. 2021 Sep 27;106(10):e3957-e3968. doi: 10.1210/clinem/dgab425.
6
Biomarker for cardiorenal syndrome risk in patients with liver cirrhosis and type 2 diabetes in Saudi Arabia.
Saudi Med J. 2024 Jul;45(7):675-684. doi: 10.15537/smj.2024.45.7.20240156.
10
The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease.
Intern Med. 2011;50(10):1081-7. doi: 10.2169/internalmedicine.50.5043. Epub 2011 May 1.

本文引用的文献

1
Atherogenic index of plasma as a predictor of coronary artery disease: a cohort study in south of Iran.
Egypt Heart J. 2024 May 28;76(1):65. doi: 10.1186/s43044-024-00497-z.
2
Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Saudi Arabia: Systematic Review and Meta-analysis.
Cureus. 2023 Jun 12;15(6):e40308. doi: 10.7759/cureus.40308. eCollection 2023 Jun.
3
Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association.
Arterioscler Thromb Vasc Biol. 2022 Jun;42(6):e168-e185. doi: 10.1161/ATV.0000000000000153. Epub 2022 Apr 14.
4
Dyslipidemia Diagnosis and Treatment: Risk Stratification in Children and Adolescents.
J Nutr Metab. 2022 Feb 21;2022:4782344. doi: 10.1155/2022/4782344. eCollection 2022.
5
Redefining non-alcoholic fatty liver disease to metabolic associated fatty liver disease: Is this plausible?
World J Hepatol. 2022 Jan 27;14(1):158-167. doi: 10.4254/wjh.v14.i1.158.
6
Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: A Review of Links and Risks.
Clin Exp Gastroenterol. 2021 Nov 17;14:457-465. doi: 10.2147/CEG.S226130. eCollection 2021.
8
Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis.
Lancet Gastroenterol Hepatol. 2021 Nov;6(11):903-913. doi: 10.1016/S2468-1253(21)00308-3. Epub 2021 Sep 21.
9
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease.
Clin Liver Dis (Hoboken). 2021 Feb 1;17(1):19-22. doi: 10.1002/cld.1017. eCollection 2021 Jan.
10
Atherogenic index of plasma as a marker of cardiovascular risk factors in Mexicans aged 18 to 22 years.
Proc (Bayl Univ Med Cent). 2020 Aug 21;34(1):22-27. doi: 10.1080/08998280.2020.1799479.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验